Adam Sperling, MD, PhD

Ohh, awesome! I was actually wondering about this exact thing recently. It's super helpful to have data to answer the question.

Congrats @paralkarlab.bsky.social!

We are profoundly grateful to announce the largest single gift in our 78-year history through a new joint commitment from Josh and Anita Bekenstein and the Jonathan Lavine and Jeannie Lavine family.

Agree 100%.

Congrats on the move.

I think I get like 3 or 4 of these a day. I seem to get a lot regarding meetings or journals focused on recycling. Not my area.

Sounds like one of those tests where it’s definitely bad if positive…

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma PURPOSEThe diagnosis of smoldering multiple myeloma (SMM) primarily relies on clinical features such as plasma cell involvement, immunoglobulin protein levels, and end-organ damage. However, as early ...

Very important new paper by Samur et al on SMM in JCO - will change our thinking! @pedalheadphx.bsky.social @myeloma-society.bsky.social @themmrf.bsky.social @imfmyeloma.bsky.social @szusmani.bsky.social

# ascopubs.org/doi/10.1200/...

Can't wait.

@paralkarlab.bsky.social
Hello, since you are a hematology/oncology influencer, could you re-post my thing about the Myeloid Workshop being on despite ASH not getting it up on the website? Thank you!

Congrats @oawlab.bsky.social! Well deserved!

Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes Cancer relapse after treatment invariably proceeds from the persistence and progression of measurable residual disease (MRD), an ultrasmall malignant population. Despite the poor prognostic impact est...

Congrats to Yu-Hsiang Chen, Pavan Bachireddy, and team at @mdanderson.bsky.social for getting this important work out. By understanding how MRD cells escape therapy at a more basic level hopefully we can eventually cure more patients with MDS. www.biorxiv.org/content/10.1...

Journalist here

I’m interested in talking to a federal agency scientist who was fired, then rehired. I can keep you anonymous. I’m on Signal ginnyg.04

Reposts are appreciated!

Anthony Letai, MD, PhD

Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration.

Learn more: bit.ly/4pRWiZy

Rapid epigenomic classification of acute leukemia - Nature Genetics The authors present a molecular classification of acute leukemia using 5-methylcytosine signatures, together with a neural network-based classifier for clinical use.

Epigenetic diagnosis of acute leukemia within two hours from sample receipt 🚀

Very happy to share the results of a great collaboration between @hovestadt.bsky.social and Griffin Labs, I co-led with @sbenfatto.bsky.social, published today in @natgenet.nature.com
📄 www.nature.com/articles/s41...
🧵1/n

Dr. Rashidian from @danafarbernews.bsky.social presenting his work at the 2025 @myeloma-society.bsky.social meeting.

Awesome! Congrats. What a cool story.

Horrible!

Alice T. Shaw named Chair of Department of Medical Oncology at Dana-Farber Cancer Institute | Dana-Farber Cancer Institute Alice T. Shaw, MD, PhD, was named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, in an announcement today.

Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology.

Learn more: bit.ly/45wiiQ6

Exciting!

What an awesome meeting. Was great to catch up with everyone.

It's my first #newPI roll call on BlueSky! Calling all new #cancer PIs who just started or who are about to start their labs! Please say hi and what you work on so I can follow you if I don't already! 😃

The Myeloid Workshop is back in ASH! Please contact the organizers if you have an exciting story that will not be out by December they are: Zuzana Tothova ,
@ernstlaboratory.bsky.social
@steidluli.bsky.social
@ericpietras.bsky.social
@kathrinbernt.bsky.social
@gritsmanlab.bsky.social

Congrats!

Super interesting. Congrats on getting this out.

And here it is! Our study in clonal hematopoiesis and Alzheimer’s disease — product of 5 years’ gestation. urldefense.proofpoint.com/v2/url?u=htt...

Major Regulatory Milestone in MM: In response to an application by I2TEAMM and IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @vincentrk.bsky.social

Was this article written by GSK?

We are proud to announce that the International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma has been published by the Journal of Clinical Oncology! ascopubs.org/doi/10.1200/...